Literature DB >> 10211483

Lipoprotein-free amyloidogenic peptides in plasma are elevated in patients with sporadic Alzheimer's disease and Down's syndrome.

E Matsubara1, J Ghiso, B Frangione, M Amari, Y Tomidokoro, Y Ikeda, Y Harigaya, K Okamoto, M Shoji.   

Abstract

About 90% of the soluble amyloid beta (sA beta) that circulates in normal human plasma is associated with lipoprotein particles. In sporadic Alzheimer's disease patients, free sA beta42 but not sA beta40 is increased approximately 2.3-fold compared with age-matched controls, although a more marked elevation (approximately 8-fold for free sA beta40 and about 20-fold for sA beta42) is found in Down's syndrome patients. The data suggest that lipoprotein-sA beta dissociation may contribute to the influx of sA beta into the brain as a result of decreased plasma clearance.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10211483

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  30 in total

1.  ApoAI deficiency results in marked reductions in plasma cholesterol but no alterations in amyloid-beta pathology in a mouse model of Alzheimer's disease-like cerebral amyloidosis.

Authors:  Anne M Fagan; Erin Christopher; Jennie W Taylor; Maia Parsadanian; Michael Spinner; Melanie Watson; John D Fryer; Suzanne Wahrle; Kelly R Bales; Steven M Paul; David M Holtzman
Journal:  Am J Pathol       Date:  2004-10       Impact factor: 4.307

Review 2.  Clinico-pathologic function of cerebral ABC transporters - implications for the pathogenesis of Alzheimer's disease.

Authors:  Jens Pahnke; Olaf Wolkenhauer; Markus Krohn; Lary C Walker
Journal:  Curr Alzheimer Res       Date:  2008-08       Impact factor: 3.498

3.  Change in plasma Aß peptides and onset of dementia in adults with Down syndrome.

Authors:  N Schupf; W B Zigman; M-X Tang; D Pang; R Mayeux; P Mehta; W Silverman
Journal:  Neurology       Date:  2010-11-02       Impact factor: 9.910

Review 4.  CR1 in Alzheimer's disease.

Authors:  Xi-Chen Zhu; Jin-Tai Yu; Teng Jiang; Ping Wang; Lei Cao; Lan Tan
Journal:  Mol Neurobiol       Date:  2014-05-04       Impact factor: 5.590

Review 5.  Neuronal life span versus health span: principles of natural selection at work in the degenerating brain.

Authors:  John C O'Leary; John Koren; Chad A Dickey
Journal:  J Mol Neurosci       Date:  2011-05-11       Impact factor: 3.444

6.  Progranulin protein levels are differently regulated in plasma and CSF.

Authors:  Alexandra M Nicholson; NiCole A Finch; Colleen S Thomas; Aleksandra Wojtas; Nicola J Rutherford; Michelle M Mielke; Rosebud O Roberts; Bradley F Boeve; David S Knopman; Ronald C Petersen; Rosa Rademakers
Journal:  Neurology       Date:  2014-04-25       Impact factor: 9.910

7.  Marked increase of beta-amyloid(1-42) and amyloid precursor protein in ventricular cerebrospinal fluid after severe traumatic brain injury.

Authors:  Annika Olsson; Ludvig Csajbok; Martin Ost; Kina Höglund; Karin Nylén; Lars Rosengren; Bengt Nellgård; Kaj Blennow
Journal:  J Neurol       Date:  2004-07       Impact factor: 4.849

8.  Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease.

Authors:  T Kawarabayashi; L H Younkin; T C Saido; M Shoji; K H Ashe; S G Younkin
Journal:  J Neurosci       Date:  2001-01-15       Impact factor: 6.167

9.  Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trial.

Authors:  Angela J Hanson; Jennifer L Bayer-Carter; Pattie S Green; Thomas J Montine; Charles W Wilkinson; Laura D Baker; G Stennis Watson; Laura M Bonner; Maureen Callaghan; James B Leverenz; Elaine Tsai; Nadia Postupna; Jing Zhang; Johanna Lampe; Suzanne Craft
Journal:  JAMA Neurol       Date:  2013-08       Impact factor: 18.302

10.  Circulating immune complexes of Abeta and IgM in plasma of patients with Alzheimer's disease.

Authors:  Andrea Marcello; Oliver Wirths; Thomas Schneider-Axmann; Malin Degerman-Gunnarsson; Lars Lannfelt; Thomas A Bayer
Journal:  J Neural Transm (Vienna)       Date:  2009-05-05       Impact factor: 3.575

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.